Infections caused by candida krusei in five transplant and two surgical patients

Surgical Infections

Volumn 10, Issue 3, 2009, Pages 265-271

  Bonatti, Hugo ^a,c,d   Stelzmueller, Ingrid ^a   Berger, Natalie ^a   Lechner, Mathias ^a   Grif, Katharina ^a   Geltner, Christian ^b   Margreiter, Raimund ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Krankenhaus Natters   (Austria)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CASPOFUNGIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANDIDA KRUSEI; CANDIDIASIS; CATHETERIZATION; CHOLANGITIS; CONTROLLED STUDY; ESOPHAGUS INJURY; FEMALE; GRAFT FAILURE; HUMAN; INTENSIVE CARE UNIT; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PLEURA EMPYEMA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CLUSTER ANALYSIS; CROSS INFECTION; DNA FINGERPRINTING; DNA, FUNGAL; ECHINOCANDINS; FEMALE; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PYRIMIDINES; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; TREATMENT OUTCOME; TRIAZOLES;

EID: 67651102678     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2008.073     Document Type: Article

References (48)

1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: How much of the promise has been realized? Nat Med 2005;11:605-613.
2. Bechstein WO, Wullstein C. [Transplantation and outcome quality](Ger). Chirurg 2002;73:576-581.
3. Singh N. Infections in solid organ transplant recipients. Curr Opin Infect Dis 1998;11:411-417.
4. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002;35:53-61.
5. Saalwachter AR, Hedrick T, Sawyer RG. The other fungi: It's not just Candida albicans anymore. Surg Infect 2006;7:143-150.
6. Groll AH, Walsh TJ. Uncommon opportunistic fungi: New nos-ocomial threats. Clin Microbiol Infect 2001;7(Suppl 2):8-24.
7. Wheat LJ, Goldman M, Sarosi G. State-of-the-art review of pulmonary fungal infections. Semin Respir Infect 2002;17: 158-181.
8. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001;7(Suppl 2):1-7.
9. Borg-von Zepelin M, Kunz L, Ruchel R, et al. Epidemiology and antifungal susceptibilities of Candida spp. to six anti-fungal agents: Results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007;60:424-428.
10. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003;17:113-134.
11. Conen A, Weisser M, Orasch Jorg C, et al. Candida krusei - a serious complication in patients with hematological malignancies: Successful treatment with caspofungin. Transplant Infect Dis 2008;10:66-70.
12. Patterson TF. The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida. Curr Infect Dis Rep 2006;8:442-448.
13. Noskin GA, Lee J, Hacek DM, et al. Molecular typing for investigating an outbreak of Candida krusei. Diagn Microbiol Infect Dis 1996;26:117-123.
14. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: A multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000;70:112-116.
15. Berger N, Wirmsberger R, Kafka R, et al. Infectious complications following 72 consecutive enteric-drained pancreas transplants. Transplant Int 2006;19:549-557.
16. Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-1696.
17. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-623.
18. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transplant Infect Dis 1999;1:50-64.
19. Tollemar J, Hockerstedt K, Ericzon BG, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: A randomized, placebo-controlled study. Transplantation 1995;59:45-50.
20. Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of as-pergillosis and other invasive mold infections after liver transplantation. Liver Transplant 2005;11:656-662.
21. Kusne K, Chakrabarti P, Akhavan-Heidari M, Corry RJ. Association of bacterial and fungal infections with surgical complications in pancreas transplant recipients. Transplantation 1999;67:S174.
22. Steurer W, Bonatti H, Obrist P, et al. Incidence of in-traabdominal infection (IAI) in a consecutive series of 40 enteric drained pancreas transplants with Fk506 and MMF immunosuppression. Transplant Int 2000;13(Suppl 1):195-198.
23. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-688.
24. Goncalves RH, Miranda ET, Zaia JE, Giannini MJ. Species diversity of yeast in oral colonization of insulin-treated diabetes mellitus patients. Mycopathologia 2006;162:83-89.
25. Kusne S, Tobin D, Pasculle AW, et al. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 1994;57:398-402.
26. Viviani MA, Tortorano AM, Malaspina C, et al. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur J Epidemiol 1992;8:433-436.
27. Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis 2000;19:96-100.
28. Stauffer J, Bonatti H, Norman K, et al. Acid blocking medication usage pre and post liver transplantation. Eur Surg 2007;39:57-60.
29. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation 2003;75:2023-2029.
30. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994;19(Suppl 1):S33-S40.
31. Golan Y. Overview of transplant mycology. Am J Health Syst Pharm 2005;62(8 Suppl 1):S17-S21.
32. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-2015.
33. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005;43: 3884-3889.
34. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
35. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533-2536.
36. Koselj M, Bren A, Kandus A, Kovac D. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplant Proc 1994;26:2823-2824.
37. Petrocheilou-Paschou V, Georgilis K, Kontoyannis D, et al. Pneumonia due to Candida krusei. Clin Microbiol Infect 2002;8:806-809.
38. Chryssanthou E, Andersson B, Petrini B, et al. Detection of Candida albicans DNA in serum by polymerase chain reaction. Scand J Infect Dis 1994;26:479-485.
39. Metwally L, Hogg G, Coyle PV, et al. Rapid differentiation between fluconazole-sensitive and -resistant species of Candida directly from positive blood-culture bottles by realtime PCR. J Med Microbiol 2007;56:964-970.
40. Wise MG, Healy M, Reece K, et al. Species identification and strain differentiation of clinical Candida isolates using the DiversiLab system of automated repetitive sequence-based PCR. J Med Microbiol 2007;56:778-787.
41. Hautala T, Ikaheimo I, Husu H, et al. A cluster of Candida krusei infections in a haematological unit. BMC Infect Dis 2007;7:97.
42. Marol S, Yücesoy M. Molecular epidemiology of Candida species isolated from clinical specimens of intensive care unit patients. Mycoses 2008;51:40-49.
43. Presterl E, Daxbock F, Graninger W, Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007;13:1072-1076.
44. Pfaller MA, Diekema DJ, Gibbs DL, et al; Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46:515-521.
45. Perfect JR. Use of newer antifungal therapies in clinical practice: What do the data tell us? Oncology 2004;18(13 Suppl 7):15-23.
46. Lopez-Ciudad V, Castro-Orjales MJ, Leon C, et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006;11:73.
47. Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-140.
48. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007;29:34-38.